PERINATAL TRIALS REPORT

PT0346

BOOST Trial

A randomised trial of oxygen therapy on growth and development of infants - the Benefits Of Oxygen Saturation Targeting (BOOST) Trial.

Plain Language Summary:      Approximately 5000 babies per year in Australia receive oxygen therapy during their hospital stay in newborn intensive care. Many are dependent on oxygen for an extended time after birth and these infants are at increased risk of poor growth and development during childhood. The optimal amount of oxygen needed to maximise infants' growth, whilst minimising the risk of handicap, remains unknown. This study seeks to answer this question by assessing both the benefits and harms of a new type of treatment, higher blood oxygen levels, in a scientifically rigorous randomised trial design.

Trial status:                         Closed to accrual

Date of accrual completion:   15/9/2000

Trial Objective:                   

1. To determine if there is a clinically important difference between study groups in terms of physical growth and neurodevelopment at 1 year corrected age.

2. To determine the benefits and harms of the treatment as measured by morbidity, mortality, and burden to the health care system and families.

Type of administration:        Multi-centre National

Principal Investigator/s:        Professor David Henderson-Smart

                                         Ph 61 2 9351 7318

                                         Email dhs@perinatal.usyd.edu.au

                                         Professor Les Irwig

                                         Ph 61 2 9351 4370

                                         Email lesi@health.usyd.edu.au

Contact Person/s:                Ms Lisa Askie

                                         Ph 61 2 9351 7739

                                         Email lisa.askie@perinatal.usyd.edu.au

© IMPACT/PSANZ 2001